Damian Crowther trained as a neurologist and ran a Cambridge dementia research lab before spending six years in AstraZeneca Neuroscience, then moved into venture as an Entrepreneur in Residence at Oxford Science Enterprises, Cambridge Innovation Capital, and the Dementia Discovery Fund, all while co-founding companies like GPnotebook, EndLyz for Parkinson's, and TRIMTECH Therapeutics, which raised $31 million in seed funding to selectively break down toxic protein aggregates. His work centers specifically on protein aggregation and how it can be used to treat neurodegeneration and inflammation, and he describes himself simply as a neuroscience entrepreneur rather than a traditional investor.